Aurobindo Pharma Limited (AUROPHARMA.NS)
NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹1,590.00 (+1.16%) as of
Key statistics
- Market cap
- 914.85B
- P/E (TTM)
- 24.84
- Forward P/E
- 17.02
- EPS (TTM)
- 64.00
- Dividend yield
- 0.00%
- 52-week range
- 1,081.40 – 1,740.00
- Beta
- 0.03
- Revenue (TTM)
- 349.35B
- Profit margin
- 10.63%
- Analyst target
- ₹1,747.70
- Volume
- 473.07k
About Aurobindo Pharma Limited
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides ointments, creams, gels, powders, transdermal, and lotions; antiretroviral drugs for PLHIV & CLHIV; and injectable products, including Penems, Penicillin, Cephalosporin, ophthalmic, inhalation, oncology, and hormone products. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Hyderabad, India
- Employees
- 29,209
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.